Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?

Takayasu Kurata, Keitaro Matsuo, Minoru Takada, Masaaki Kawahara, Masahiro Tsuji, Yuka Matsubara, Nagahiro Otani, Shigeki Matsuyama, Kenya Muraishi, Tetsuya Fujita, Masato Ishikawa, Keita Koyano, Isamu Okamoto, Taroh Satoh, Kenji Tamura, Kazuhiko Nakagawa, Masahiro Fukuoka

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: It is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately. METHODS: The authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib. RESULTS: The median survival time increased 0.0375 month with each 1% increase in stable disease rate (p = 0.039), and each 1% increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival. CONCLUSIONS: To obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs.

Original languageEnglish
Pages (from-to)684-691
Number of pages8
JournalJournal of Thoracic Oncology
Volume1
Issue number7
Publication statusPublished - Sep 1 2006
Externally publishedYes

Fingerprint

Cytotoxins
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
PubMed
Databases
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? / Kurata, Takayasu; Matsuo, Keitaro; Takada, Minoru; Kawahara, Masaaki; Tsuji, Masahiro; Matsubara, Yuka; Otani, Nagahiro; Matsuyama, Shigeki; Muraishi, Kenya; Fujita, Tetsuya; Ishikawa, Masato; Koyano, Keita; Okamoto, Isamu; Satoh, Taroh; Tamura, Kenji; Nakagawa, Kazuhiko; Fukuoka, Masahiro.

In: Journal of Thoracic Oncology, Vol. 1, No. 7, 01.09.2006, p. 684-691.

Research output: Contribution to journalArticle

Kurata, T, Matsuo, K, Takada, M, Kawahara, M, Tsuji, M, Matsubara, Y, Otani, N, Matsuyama, S, Muraishi, K, Fujita, T, Ishikawa, M, Koyano, K, Okamoto, I, Satoh, T, Tamura, K, Nakagawa, K & Fukuoka, M 2006, 'Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?', Journal of Thoracic Oncology, vol. 1, no. 7, pp. 684-691.
Kurata, Takayasu ; Matsuo, Keitaro ; Takada, Minoru ; Kawahara, Masaaki ; Tsuji, Masahiro ; Matsubara, Yuka ; Otani, Nagahiro ; Matsuyama, Shigeki ; Muraishi, Kenya ; Fujita, Tetsuya ; Ishikawa, Masato ; Koyano, Keita ; Okamoto, Isamu ; Satoh, Taroh ; Tamura, Kenji ; Nakagawa, Kazuhiko ; Fukuoka, Masahiro. / Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?. In: Journal of Thoracic Oncology. 2006 ; Vol. 1, No. 7. pp. 684-691.
@article{f2452ed7ec084bf596f01294d2ed1efd,
title = "Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?",
abstract = "BACKGROUND: It is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately. METHODS: The authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib. RESULTS: The median survival time increased 0.0375 month with each 1{\%} increase in stable disease rate (p = 0.039), and each 1{\%} increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival. CONCLUSIONS: To obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs.",
author = "Takayasu Kurata and Keitaro Matsuo and Minoru Takada and Masaaki Kawahara and Masahiro Tsuji and Yuka Matsubara and Nagahiro Otani and Shigeki Matsuyama and Kenya Muraishi and Tetsuya Fujita and Masato Ishikawa and Keita Koyano and Isamu Okamoto and Taroh Satoh and Kenji Tamura and Kazuhiko Nakagawa and Masahiro Fukuoka",
year = "2006",
month = "9",
day = "1",
language = "English",
volume = "1",
pages = "684--691",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",

}

TY - JOUR

T1 - Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer?

AU - Kurata, Takayasu

AU - Matsuo, Keitaro

AU - Takada, Minoru

AU - Kawahara, Masaaki

AU - Tsuji, Masahiro

AU - Matsubara, Yuka

AU - Otani, Nagahiro

AU - Matsuyama, Shigeki

AU - Muraishi, Kenya

AU - Fujita, Tetsuya

AU - Ishikawa, Masato

AU - Koyano, Keita

AU - Okamoto, Isamu

AU - Satoh, Taroh

AU - Tamura, Kenji

AU - Nakagawa, Kazuhiko

AU - Fukuoka, Masahiro

PY - 2006/9/1

Y1 - 2006/9/1

N2 - BACKGROUND: It is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately. METHODS: The authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib. RESULTS: The median survival time increased 0.0375 month with each 1% increase in stable disease rate (p = 0.039), and each 1% increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival. CONCLUSIONS: To obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs.

AB - BACKGROUND: It is controversial whether achieving stable disease leads to a survival benefit and whether the importance of achieving stable disease differs between cytotoxic agents and molecular targeted agents. To examine these questions, the authors retrospectively reviewed phase II and III studies in the second-line setting for advanced non-small cell lung cancer using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic agents separately. METHODS: The authors chose 45 trials for the chemotherapy group and nine for the EGFR TKI group by searching the PubMed database. All nine trials in the EGFR TKI group concern gefitinib and erlotinib. RESULTS: The median survival time increased 0.0375 month with each 1% increase in stable disease rate (p = 0.039), and each 1% increase in response rate resulted in 0.0744 (p < 0.001) month of median survival time in the analysis combined with both cytotoxic agents and EGFR TKIs. Main and interaction terms for EGFR TKI treatment were not statistically significant. With respect to time to progression, only response rate showed a statistically significant relationship with survival. CONCLUSIONS: To obtain response seems to be more important than to achieve stable disease for both cytotoxic agents and EGFR TKIs, although achieving stable disease is still valuable. The relationship between survival and response or stable disease appears similar for cytotoxic agents and EGFR TKIs.

UR - http://www.scopus.com/inward/record.url?scp=34247863893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247863893&partnerID=8YFLogxK

M3 - Article

C2 - 17409937

AN - SCOPUS:34247863893

VL - 1

SP - 684

EP - 691

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -